Omada Health, Inc. (OMDA) · Nov 5, 2026 · Earnings

Omada Health earnings beat as EBITDA guidance jumps

Beat — Revenue $91.3M vs ~$87.4M consensus; diluted EPS $0.10 vs ~$0.03 GAAP consensus

Omada Health earnings beat revenue expectations, while stronger margins and execution drive a sharp increase in full-year adjusted EBITDA guidance.

Omada is scaling a virtual-first chronic-care platform across diabetes, hypertension, weight management and related conditions, with national partners and enrollment growth supporting a longer-term profitability push. Before this filing, management had already raised 2026 guidance after a strong second quarter and set long-term targets of at least 20% annual revenue growth, 80% non-GAAP gross margin and 30% adjusted EBITDA margin.

The quarter cleared an already-raised bar. Revenue reached $91.3 million, up 34% year over year, versus published consensus of roughly $87.4 million; diluted GAAP EPS was $0.10 versus a published estimate near $0.03. The filing also reports 1.1 million members, up 36%, and a 76% GAAP gross margin. 〔0〕

MetricQ3 2026Q3 2025Consensus / prior guide
Revenue (Income Statement)$91.3M (+34%)$68.0M~$87.4M
Diluted EPS (Income Statement)$0.10$(0.06)~$0.03
GAAP gross margin (Non-GAAP reconciliation)76%66%
Adjusted EBITDA (Adjusted EBITDA reconciliation)$12.4M$2.4M
Adjusted EBITDA margin (Adjusted EBITDA reconciliation)14%4%
FY2026 adjusted EBITDA guidance (Outlook)$32M–$34M$21M–$27M prior guide

The more important signal is the profitability upgrade. Omada lifted full-year adjusted EBITDA guidance to $32 million–$34 million from $21 million–$27 million, a much larger increase than a routine quarterly update. Q3 adjusted EBITDA reached $12.4 million, while nine-month adjusted EBITDA was already $24.1 million, showing that the improvement is coming from actual operating leverage rather than only a more optimistic narrative.

Growth is still being converted into better economics. Revenue growth remained strong, gross margin expanded to 76% from 66% a year earlier, and operating income turned positive at $4.8 million versus a $2.5 million loss. The company also generated $2.5 million of free cash flow in the first nine months versus negative $7.6 million a year earlier, although the balance-sheet improvement includes $20.0 million of proceeds from stock-option exercises rather than only internally generated cash.

The remaining question is durability, not near-term execution. Omada is still investing heavily in sales and marketing, research and development and general administration, while its long-term 30% adjusted EBITDA margin target remains far above the current 14% quarterly margin. The filing therefore materially strengthens the profitable-growth story, but does not by itself prove that the current margin trajectory can reach the long-term target.

Bottom line: This was more than a clean quarterly beat: Omada delivered faster growth, positive GAAP operating income and a substantial EBITDA guidance increase. It advances the company’s core story from “scaling toward profitability” to “scaling with profitability already visible.”

What to watch next

CEO transition to Wei-Li Shao, January 1, 2027

Original filing on SEC EDGAR

More Omada Health, Inc. news

Omada Health earnings beat as EBITDA guidance jumps | OMDA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.